Free Trial
NASDAQ:PTIX

Atrinsic 11/14/2023 Earnings Report

Atrinsic logo
$3.15 +0.05 (+1.61%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$3.13 -0.02 (-0.63%)
As of 09/5/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atrinsic EPS Results

Actual EPS
-$4.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Wednesday, September 10, 2025, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
Protagenic Therapeutics swaps warrants for shares
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile

More Earnings Resources from MarketBeat